Pharmaceutical products

Our pharmaceutical products are at the moment based on two patented, synthetic anthocyanin molecules. These small molecules are: BSC-3-Glucopyranoside (BSD3G) and BSD-3-Glucopyranoside (BSC3G).

These two synthetic anthocyanin small molecules have been synthesiced through 6 years of intensive basic research and development within organic chemistry. Both BSC3G and BSD3G are at the moment in an up-scaling prosess .

BSC3G has fore some time been scaled up to a magnitude of one million times, while BSD3G has passed through the one thousand times threshold.  Shortly these molecules are expected to be available in a feasible pharmaceutical industrial magnitude.

Both the patented, synthetic small molecules have for some time being studied clinically with the purpose of discovering and creating medical applications. The tree main medical areas being studied at the moment are:

CIF-C/D-3G               Medicine against Chronic Inflammation, Medical platform for different  medical applications.
                                   ( Norway/Peoples Republic of China)
CAN-C/D-3G             Cancer impeding medicine (USA)
HPT-C/D-3G              Hypertension medicine (Norway)

All three potential medicines are in early stages. Significant results from clinic studies have been proven. Both cell line studies, animal studies and human studies are taken place.

Biolink Group will soon, after research and development since the establishment of the company in 1998, be ready to enter into an “Alliance Management Program” with a well established pharmaceutical company, having resources enough to proceed from phase 0/I and further into phase I, II, III and IV with one or more of these medical projects.

A clinic study on anthocyanins (Medox®/MP865®) and Chronic Inflammation, being executed at The University Hospital of Ullevål and The University of Oslo, among other sponsored by the Norwegian Cancer Society, has already been published in “Journal of Nutrition”, August 2007, USA.